Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
LBT Innovations Limited ( (AU:CC5) ) has provided an announcement.
Clever Culture Systems Ltd has announced the sale of an APAS® Independence instrument to Novo Nordisk in Europe, marking a significant step in their strategy to engage with major pharmaceutical manufacturers. Novo Nordisk will evaluate the APAS® technology for potential implementation across their manufacturing network, assessing its performance in reading microbiology culture plates used in environmental monitoring. This sale is part of CCS’s broader strategy to target top-tier multinational pharmaceutical manufacturers, which has already resulted in engagements with companies like AstraZeneca and Bristol Myers Squibb. The successful execution of this strategy highlights the significant market opportunity for CCS’s APAS® Independence technology.
More about LBT Innovations Limited
Clever Culture Systems Ltd, based in Adelaide, South Australia, specializes in intelligent automation solutions for microbiology laboratories. The company has developed the Automated Plate Assessment System (APAS® Independence), which uses artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. This technology is the only US FDA-cleared AI technology for automated culture plate reading and is marketed to microbiology laboratories in the pharmaceutical manufacturing sector and clinical laboratories for infectious diseases diagnostics.
Average Trading Volume: 883,054
Technical Sentiment Signal: Hold
Current Market Cap: A$30.03M
Learn more about CC5 stock on TipRanks’ Stock Analysis page.